Humanized Chondroitinase ABC Sensitizes Glioblastoma Cells to Temozolomide

INTRODUCTION: Malignant gliomas (GBMs) are extremely aggressive and have a median survival of approximately 15 months. Current treatment modalities, which include surgical resection, radiation and chemotherapy, have done little to prolong the lives of GBM patients. Chondroitin sulfate proteoglycans...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gene Med
Autors principals: Jaime-Ramirez, Alena Cristina, Dmitrieva, Nina, Yoo, Ji Young, Banasavadi-Siddegowda, Yeshavanth, Zhang, Jianying, Relation, Theresa, Bolyard-Blessing, Chelsea, Wojton, Jeffrey, Kaur, Balveen
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5382089/
https://ncbi.nlm.nih.gov/pubmed/28087981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgm.2942
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars